June marks AML Awareness Month. It is a time to understand acute myeloid leukaemia. AML is a blood cancer needing quick ...

Acute Myeloid leukaemia AML is a fast-growing cancer of the bone marrow that disrupts blood cell production It differs from ...

An announcement from Moleculin Biotech ( ($MBRX) ) is now available. On July 9, 2025, Moleculin Biotech announced that the Regulation Agency for ...

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making ...

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, ...

Researchers have uncovered a crucial enzyme responsible for a specific chemical modification linked to the growth of a severe ...

After a leukemia diagnosis, a Rome family found support at an Atlanta Ronald McDonald House while their son underwent chemotherapy at Children’s Healthcare of Atlanta.

A panelist discusses how the ASCERTAIN-V study demonstrated that an all-oral combination of decitabine-cedazuridine plus venetoclax achieved a 47% complete response rate and 15.5-month median overall ...

FLT3-ITD MRD dynamics predicted relapse risk and shaped response to gilteritinib maintenance in post-transplant AML.